What does Innocrin Pharmaceuticals do?
Innocrin Pharmaceuticals, is a pharmaceutical company, which discovers and develops oral inhibitors for the treatment of castration- resistant prostate cancer and best in class oral inhibitors of CYP17 lyase, which is a validated enzyme target for the treatment and for hormone driven conditions such as endometriosis, breast cancer and congenial adrenal hyperplasia. Innocrin Pharmaceutical’s VT-464, which is under pipeline, is a dual mechanism lyase selective CYP17 inhibitor and androgen receptor antagonist which disrupts the validated biochemical pathways necessary for prostrate cancer growth, AR transcriptional signaling and androgen biosynthesis.
How much Innocrin Pharmaceuticals was funded?
Innocrin Pharmaceuticals has raised $28M in Series D on April 14th, 2015 from Eshelman Ventures and Fred Eshelman. Other investors include Lilly Ventures, Novartis Venture Fund, Intersouth Partners, Hatteras Venture Partners and A&B Equity Holdings.
$8M in Debt Financing on December 10, 2014
What is next for Innocrin Pharmaceuticals?
The latest investment in Innocrin Pharmaceuticals is an exciting investment opportunity and its pipeline, VT-464, will contribute to the advancements in treatment of difficult cancers. It plans to use the funds to expedite parallel Phase 2 CRPC program studies which are led by the NCI and MSK. As a part of the latest funding Fred Eshelman, PharmD., has joined the Board of Directors. His deep experience in the corporate development and pharmaceutical field will be invaluable to the start up
More about Innocrin Pharmaceuticals
Innocrin Pharmacetucials was founded in 2004. It has its headquarters in Durham, NC. Innocrin discovers and develops novel, and the best in class oral inhibitors of CYP 17 lyase, a validated enzyme target for the treatment of castration resistant prostate cancer.Innocrin owns VT-464 and structurally related classes of CYP-17 inhibitors, which has high potential for treating breast cancer ans for non-oncologic syndromes which are caused due to excess hormones such as PCOD, endometriosis and congenital adrenal hyperplasia.